Capnocytophaga canimorsus: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 26: Line 26:
Capnocytophaga canimorsus was AKA Dysgonic fermenter type 2 (DF2).
Capnocytophaga canimorsus was AKA Dysgonic fermenter type 2 (DF2).
===Antimicrobial Regimen===
===Antimicrobial Regimen===
:*'''1.Severe Cellulitis/Sepsis or Endocarditis'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:* Capnocytophaga canimorsus<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
::*Preferred regimen
::* 1. '''Severe cellulitis/sepsis or endocarditis'''
:::*Beta-lactam/beta-lactamase inhibitor : [[Ampicillin]]/[[sulbactam]] 3 g IV q6h
:::* Preferred regimen (1) (Beta-lactam/beta-lactamase inhibitor): [[Ampicillin]]/[[sulbactam]] 3 g IV q6h  
:::*Non-beta-lactamase producing : [[Penicillin G]] 2-4MU q4h IV
:::* Preferred regimen (2) (Non-beta-lactamase producing): [[Penicillin G]] 2-4 MU IV q24h
::*Alternative regimen : [[Ceftriaxone]] 1-2 g IV q24h {{or}} [[Meropenem]] 1 g IV q8h.
:::* Alternative regimen (1): [[Ceftriaxone]] 1-2 g IV q24h  
 
:::* Alternative regimen (2): [[Meropenem]] 1 g IV q8h
:*'''2.Complicated infections or Immunocompromise'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:::* Alternative regimen (3) (complicated infections or immunocompromise): [[Clindamycin]] 600 mg IV q8h may be combined with above agents
::*Preferred regimen : [[Clindamycin]] 600 mg IV q8h may be combined with above agents
:::* Note (1): Resistance to aztreonam described, and variable susceptibility reported to TMP-SMX and aminoglycosides
::*Note (1): Resistance to aztreonam described, and variable susceptibility reported to [[TMP-SMX]] and aminoglycosides.
:::* Note (2): For endocarditis, alternatives to penicillins not well established, treated for duration of 6 weeks  
::*Note (2): For endocarditis, alternatives to penicillins not well established, treated for duration of 6 weeks. For non-endocarditis infections, duration not well established, but most authorities recommend at least 14-21 days of therapy.
:::* Note (3): For non-endocarditis infections, duration not well established, but most authorities recommend at least 14-21 days of therapy
 
::* 2. '''Mild cellulitis/dog or cat bites'''
:*'''3.Mild Cellulitis/Dog or Cat Bites'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:::* Preferred regimen (1): [[Amoxicillin/clavulanate]] 500 mg PO q8h or 875 mg PO bid  
::*Preferred regimen : [[Amoxicillin/clavulanate]] 500 mg PO q8h or 875 mg PO bid {{or}} [[Amoxicillin]] 500 mg PO q8h.
:::* Preferred regimen (2): [[Amoxicillin]] 500 mg PO q8h
::*Alternative regimen : [[Clindamycin]] 300 mg PO q6h {{or}} [[Doxycycline]] 100 mg PO bid {{or}} [[Clarithromycin]] 500 mg PO bid {{or}} [[Moxifloxacin]] 400 mg PO OD.
:::* Alternative regimen (1): [[Clindamycin]] 300 mg PO q6h  
 
:::* Alternative regimen (2): [[Doxycycline]] 100 mg PO bid  
:*'''4.Meningitis or brain abscess'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:::* Alternative regimen (3): [[Clarithromycin]] 500 mg PO bid  
::*Preferred regimen : Use [[Ceftriaxone]] 2 g IV q12h {{and}} [[Ampicillin]] 2 g IV q4h
:::* Alternative regimen (4): [[Moxifloxacin]] 400 mg PO qd
::*If Beta-lactamase producing or polymicrobial brain abscess : [[Imipenem]]/[[cilastin]] 1000 mg q6-8h {{and}} [[Clindamycin]] 600 mg IV q8h
::* 3. '''Meningitis or brain abscess'''
 
:::* Preferred regimen (1): [[Ceftriaxone]] 2 g IV q12h {{and}} [[Ampicillin]] 2 g IV q4h
:*'''5.Prevention'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:::* Preferred regimen (2) (if beta-lactamase producing or polymicrobial brain abscess): [[Imipenem]]/[[Cilastin]] 1000 mg q6-8h {{and}} [[Clindamycin]] 600 mg IV q8h
::*Although no firm data supports this recommendation, many clinicians do give prophylaxis for dog and cat bites in asplenic patients with [[amoxicillin/clavulanate]] for 7-10 days.
::* 4. '''Prevention'''
:::* Although no firm data supports this recommendation, many clinicians do give prophylaxis for dog and cat bites in asplenic patients with [[Amoxicillin/clavulanate]] for 7-10 days


==References==
==References==

Latest revision as of 18:09, 28 July 2015

Capnocytophaga
Scientific classification
Kingdom: Bacteria
Phylum: Bacteroidetes
Class: Flavobacteria
Order: Flavobacteriaceae
Family: Flavobacteriaceae
Genus: Capnocytophaga
Species: C. canimorsus
Brenner et al, 1990
Binomial name
Capnocytophaga canimorsus

WikiDoc Resources for Capnocytophaga canimorsus

Articles

Most recent articles on Capnocytophaga canimorsus

Most cited articles on Capnocytophaga canimorsus

Review articles on Capnocytophaga canimorsus

Articles on Capnocytophaga canimorsus in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Capnocytophaga canimorsus

Images of Capnocytophaga canimorsus

Photos of Capnocytophaga canimorsus

Podcasts & MP3s on Capnocytophaga canimorsus

Videos on Capnocytophaga canimorsus

Evidence Based Medicine

Cochrane Collaboration on Capnocytophaga canimorsus

Bandolier on Capnocytophaga canimorsus

TRIP on Capnocytophaga canimorsus

Clinical Trials

Ongoing Trials on Capnocytophaga canimorsus at Clinical Trials.gov

Trial results on Capnocytophaga canimorsus

Clinical Trials on Capnocytophaga canimorsus at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Capnocytophaga canimorsus

NICE Guidance on Capnocytophaga canimorsus

NHS PRODIGY Guidance

FDA on Capnocytophaga canimorsus

CDC on Capnocytophaga canimorsus

Books

Books on Capnocytophaga canimorsus

News

Capnocytophaga canimorsus in the news

Be alerted to news on Capnocytophaga canimorsus

News trends on Capnocytophaga canimorsus

Commentary

Blogs on Capnocytophaga canimorsus

Definitions

Definitions of Capnocytophaga canimorsus

Patient Resources / Community

Patient resources on Capnocytophaga canimorsus

Discussion groups on Capnocytophaga canimorsus

Patient Handouts on Capnocytophaga canimorsus

Directions to Hospitals Treating Capnocytophaga canimorsus

Risk calculators and risk factors for Capnocytophaga canimorsus

Healthcare Provider Resources

Symptoms of Capnocytophaga canimorsus

Causes & Risk Factors for Capnocytophaga canimorsus

Diagnostic studies for Capnocytophaga canimorsus

Treatment of Capnocytophaga canimorsus

Continuing Medical Education (CME)

CME Programs on Capnocytophaga canimorsus

International

Capnocytophaga canimorsus en Espanol

Capnocytophaga canimorsus en Francais

Business

Capnocytophaga canimorsus in the Marketplace

Patents on Capnocytophaga canimorsus

Experimental / Informatics

List of terms related to Capnocytophaga canimorsus


Capnocytophaga canimorsus is a Gram-negative bacillus (rod-shaped) bacterium that causes a zoonotic disease in mostly asplenic patients. It is a member of the normal gingival flora of dogs and cats. It causes fulminant sepsis with disseminated intravascular coagulation (DIC), in typically asplenic patients.

Treatment

Treatment is via antibiotics with the possible aid of activated protein C or plasmapheresis in severe cases.

Following animal bites, co-amoxiclav is often given to asplenic individuals to prevent disseminated infection; but in patients who are allergic to penicillins, the combination of doxycycline and metronidazole (to cover anaerobic organisms) may be used instead.

In patients with sepsis, treatment with imipenem, clindamycin, or a penicillin-β-lactamase inhibitor combination (e.g., co-amoxiclav or piperacillin-tazobactam) should be used.[1] Doxycycline is active in vitro[2][3] but there is little experience in using it in treating sepsis, and in many countries there is no intravenous form available, which suggests that it should be reserved for when no other options are available.

Capnocytophaga canimorsus was AKA Dysgonic fermenter type 2 (DF2).

Antimicrobial Regimen

  • Capnocytophaga canimorsus[4]
  • 1. Severe cellulitis/sepsis or endocarditis
  • Preferred regimen (1) (Beta-lactam/beta-lactamase inhibitor): Ampicillin/sulbactam 3 g IV q6h
  • Preferred regimen (2) (Non-beta-lactamase producing): Penicillin G 2-4 MU IV q24h
  • Alternative regimen (1): Ceftriaxone 1-2 g IV q24h
  • Alternative regimen (2): Meropenem 1 g IV q8h
  • Alternative regimen (3) (complicated infections or immunocompromise): Clindamycin 600 mg IV q8h may be combined with above agents
  • Note (1): Resistance to aztreonam described, and variable susceptibility reported to TMP-SMX and aminoglycosides
  • Note (2): For endocarditis, alternatives to penicillins not well established, treated for duration of 6 weeks
  • Note (3): For non-endocarditis infections, duration not well established, but most authorities recommend at least 14-21 days of therapy
  • 2. Mild cellulitis/dog or cat bites
  • 3. Meningitis or brain abscess
  • 4. Prevention
  • Although no firm data supports this recommendation, many clinicians do give prophylaxis for dog and cat bites in asplenic patients with Amoxicillin/clavulanate for 7-10 days

References

  1. Jolivet-Gougeon A, Sixou J, Tamanai-Shacoori Z, Bonnaure-Mallet M (2007). "Antimicrobial treatment of Capnocytophaga infections". Int J Antimicrob Agents. 29 (4): 367–373. doi:10.1016/j.ijantimicag.2006.10.005.
  2. Chraibi DI, Girond S, Michel G (1990). "Evaluation of the activity of four antimicrobial agents using an in vitro rapid micromethod against oral streptococci and various bacterial strains implicated in periodontitis". J Periodontal Res. 25 (4): 201&ndash, 6. PMID 2142728.
  3. Heimdahl A, Nord CE (1988). "Antimicrobial agents in the treatment of periodontal diseases: special aspects on tetracycline and doxycycline". Scand J Infect Dis Suppl. 53: 35&ndash, 45. PMID 3047856.
  4. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

External links



Template:WS